News Image

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Provided By GlobeNewswire

Last update: Feb 11, 2025

-- Targeting Unmet Needs for Treating Solid Tumors--

REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License Agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray.

Read more at globenewswire.com

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (6/6/2025, 8:00:02 PM)

After market: 0.3232 +0 (+0.06%)

0.323

+0.03 (+8.39%)



Find more stocks in the Stock Screener

BOLT Latest News and Analysis

ChartMill News Image5 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Mentions: PVH MFI PL VRNT ...

Follow ChartMill for more